Title:
USE OF ANTIBODY AGAINST O-ACETYLATED GD2 GANGLIOSIDE TO IMPROVE THERAPEUTIC POTENTIAL OF DRUGS
Document Type and Number:
Japanese Patent JP2023065373
Kind Code:
A
Abstract:
To provide new compositions and kits to overcome drawbacks of drug uptake in cancer cells and tumors to improve their therapeutic potential and also to reduce their side effects such as toxicity.SOLUTION: A composition for use in delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside comprises (i) at least one anti-cancer agent having a molecular mass of 100 to 200,000 Daltons, and (ii) at least one multimeric antibody recognizing the OAcGD2 ganglioside, where the multimeric antibody comprises a light chain variable region (VL) polypeptide and a heavy chain variable region (VH), where the multimeric antibody creates non-selective pores on a cell membrane, and where the multimeric antibody comprises a IgG1 constant region engineered to have multimerization properties.SELECTED DRAWING: None
Inventors:
Burkle Stephane
florence julian
Farage Sebastian
Le Doussal Jean-Marc
Coshonno Dennis
Therm Michael
Assoline Brigitte
florence julian
Farage Sebastian
Le Doussal Jean-Marc
Coshonno Dennis
Therm Michael
Assoline Brigitte
Application Number:
JP2023014183A
Publication Date:
May 12, 2023
Filing Date:
February 01, 2023
Export Citation:
Assignee:
Aussie Dee 2 Pharma
Nantes Université
Center Nacional de la Shellche Scientific
Intherm (Institute National de la Sante e de la Shelche Medical)
Institute de Cancellosiers de Luest
Nantes Université
Center Nacional de la Shellche Scientific
Intherm (Institute National de la Sante e de la Shelche Medical)
Institute de Cancellosiers de Luest
International Classes:
A61K47/68; A61K31/4745; A61K31/675; A61K31/704; A61K31/7088; A61K31/713; A61K45/00; A61P35/00; A61P35/02; A61P35/04
Attorney, Agent or Firm:
Masayuki Masabayashi
Hayashi Kazuyoshi
Tetsuo Shiba
Mitsuru Iwaike
Hayashi Kazuyoshi
Tetsuo Shiba
Mitsuru Iwaike